Drug inspection seminar between China CFDI and British MHRA was successfully held online on October 21, 2021. The conference was organized under the framework of the "2021 Sino-British Drug Regulatory Cooperation Project Plan" jointly signed by the National Medical Products Administration (NMPA) and the British Medicines and Healthcare Products Regulatory Agency (MHRA). The meeting received strong support from the British Embassy in China.

At this meeting, the two parties respectively introduced the work functions of their agencies, drug regulations, and the current status of drug inspection, etc., shared the situation and experience of remote inspections in the context of the epidemic, and carried out in-depth discuss on remote inspection. This seminar enhanced the understanding of each drug inspection system and related regulations, expanded the international vision of China's inspectors, and further promoted the integration of China's drug regulatory system with international standards.

Dr. Samantha Atkinson, Chief Quality and Access Senior Officer of MHRA, and 3 related inspection experts, Mr. Richard Cowin, Health Counselor of the British Embassy, colleagues from the Department of Drug Regulation of NMPA, Dong Jiangping, Deputy Director of CFDI, and more than 30 national inspectors participated in the Seminar.